Rezolute, Inc. (RZLT)
| Market Cap | 329.27M +37.4% |
| Revenue (ttm) | n/a |
| Net Income | -84.23M |
| EPS | -0.91 |
| Shares Out | 103.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,322,726 |
| Open | 3.270 |
| Previous Close | 3.210 |
| Day's Range | 3.150 - 3.345 |
| 52-Week Range | 1.070 - 11.457 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 9.67 (+205.05%) |
| Earnings Date | May 13, 2026 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price target is $9.67, which is an increase of 205.05% from the latest price.
News
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all for...
Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026
Rezolute (RZLT) announced that expanded analyses from the Phase 3 sunRIZE study of ersodetug in patients with congenital HI were presented at the Pediatric Endocrine Society 2026 Annual Meeting. The…
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared t...
Rezolute, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rezolute, Inc., (“Rezolute" or the "Company") (NASDAQ: RZLT) investors that the firm has initiated an investigation into po...
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates
Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI
As previously reported, Wedbush analyst Yun Zhong upgraded Rezolute (RZLT) to Outperform from Neutral with a price target of $5, up from $2, based on the update following a Type…
Rezolute upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Rezolute (RZLT) to Outperform from Neutral with a price target of $5, up from $2.
Rezolute provides update on sunRIZE study following Type B meeting with FDA
Rezolute (RZLT) announced outcomes from an in-person Type B meeting with the FDA held, related to sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy stud...
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all f...
Rezolute to Participate in the Citizens Life Sciences Conference
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all f...
Rezolute management to meet with Maxim
Meeting to be held in Miami on March 11 hosted by Maxim.
Rezolute reports Q2 EPS (22c), consensus (18c)
Cash, cash equivalents and investments in marketable securities were $132.9M as of December 31, 2025, compared with $167.9M as of June 30, 2025.
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all fo...
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all fo...
Rezolute price target raised to $2 from $1 at Wedbush
Wedbush raised the firm’s price target on Rezolute (RZLT) to $2 from $1 and keeps a Neutral rating on the shares. The firm notes the company reported PK/PD data and…
Rezolute shares findings from Expanded Access Program in tumor HI
Over the past two years, Rezolute (RZLT) has collaborated with investigators across the United States and in Europe to provide ersodetug to more than a dozen patients with severe and…
Rezolute shares observations from Phase 3 sunRIZE study in congenital HI
Rezolute (RZLT) shared observations from the Phase 3 sunRIZE study in patients with congenital HI and provided details on the treatment of tumor HI patients with ersodetug under the Company’s…
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for ...
Rezolute price target lowered to $4 from $20 at Maxim
Maxim analyst Jason McCarthy lowered the firm’s price target on Rezolute (RZLT) to $4 from $20 but keeps a Buy rating on the shares. The firm cites the company’s Phase…
Rezolute price target lowered to $6 from $15 at Guggenheim
Guggenheim lowered the firm’s price target on Rezolute (RZLT) to $6 from $15 and keeps a Buy rating on the shares. Following the failure of the sunRIZE trial, the firm…
Rezolute price target lowered to $5 from $14 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Rezolute (RZLT) to $5 from $14 and keeps a Buy rating on the shares. The firm is “surprised and…
Rezolute downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Albert Lowe downgraded Rezolute (RZLT) to Hold from Buy with a $2 price target after the Phase 3 study of ersodetug in congenital hyperinsulinism missed its endpoint. Published…
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
LOS ANGELES--(BUSINESS WIRE)--Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT.
Rezolute price target lowered to $5 from $17 at BTIG
BTIG analyst Julian Harrison lowered the firm’s price target on Rezolute (RZLT) to $5 from $17 and keeps a Buy rating on the shares. The firm “conservatively” removed ersodetug in…
Rezolute downgraded to Market Perform from Outperform at Citizens
Citizens downgraded Rezolute (RZLT) to Market Perform from Outperform.